Janux Therapeutics, Inc. (NASDAQ:JANX) Major Shareholder Ventures Xi L.P. Avalon Sells 49,231 Shares

Janux Therapeutics, Inc. (NASDAQ:JANX) major shareholder Ventures Xi L.P. Avalon sold 49,231 shares of the stock in a transaction dated Friday, September 27th. The stock was sold at an average price of $46.45, for a total transaction of $2,286,779.95. Following the transaction, the insider now directly owns 6,926 shares in the company, valued at approximately $321,712.70. The transaction was disclosed in a filing with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Ventures Xi L.P. Avalon also recently made the following trade(s):

• On Monday, September 30th, Ventures Xi L.P. Avalon sold 958 shares of Janux Therapeutics stock. The stock was sold at an average price of $46.24, for a total value of $44,297.92.
• On Thursday, September 12th, Ventures Xi L.P. Avalon sold 158,031 shares of Janux Therapeutics stock. The shares were sold at an average price of $47.00, for a total value of $7,427,457.00.
• On Friday, September 6th, Ventures Xi L.P. Avalon sold 108,365 shares of Janux Therapeutics stock. The stock was sold at an average price of $42.00, for a total value of $4,551,330.00.
• On Monday, September 9th, Ventures Xi L.P. Avalon sold 2,182 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.33, for a total transaction of $92,364.06.

Janux Therapeutics Trading Down 1.8 %

Shares of JANX traded down $0.82 on Monday, reaching $45.43. 879,722 shares of the company’s stock traded hands, compared to its average volume of 722,238. The stock’s 50 day simple moving average is $43.92 and its two-hundred day simple moving average is $44.59. The stock has a market cap of $2.36 billion, a PE ratio of -37.91 and a beta of 3.57. Janux Therapeutics, Inc. has a 52-week low of $5.65 and a 52-week high of $65.60.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Wednesday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.20. The firm had revenue of $8.90 million during the quarter, compared to analyst estimates of $0.77 million. Janux Therapeutics had a negative return on equity of 8.78% and a negative net margin of 291.17%. The firm’s quarterly revenue was up 709.1% on a year-over-year basis. Analysts forecast that Janux Therapeutics, Inc. will post -1.18 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Stifel Nicolaus assumed coverage on shares of Janux Therapeutics in a research note on Friday, September 6th. They issued a “buy” rating and a $70.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price target on shares of Janux Therapeutics in a research report on Monday, August 19th. Wedbush reissued an “outperform” rating and set a $74.00 price objective on shares of Janux Therapeutics in a report on Thursday, August 8th. Cantor Fitzgerald restated an “overweight” rating and issued a $100.00 target price on shares of Janux Therapeutics in a report on Monday, September 16th. Finally, Scotiabank decreased their price target on Janux Therapeutics from $47.00 to $42.00 and set a “sector perform” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Janux Therapeutics has an average rating of “Moderate Buy” and an average target price of $66.13.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Capstone Investment Advisors LLC bought a new stake in shares of Janux Therapeutics in the 1st quarter worth approximately $1,969,000. Janus Henderson Group PLC lifted its position in shares of Janux Therapeutics by 1.8% during the 1st quarter. Janus Henderson Group PLC now owns 1,965,546 shares of the company’s stock valued at $73,961,000 after buying an additional 34,069 shares during the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Janux Therapeutics during the 1st quarter worth $739,000. Virtu Financial LLC purchased a new stake in Janux Therapeutics in the 1st quarter worth about $609,000. Finally, Vanguard Group Inc. raised its stake in Janux Therapeutics by 38.6% in the 1st quarter. Vanguard Group Inc. now owns 1,357,960 shares of the company’s stock valued at $51,127,000 after acquiring an additional 378,477 shares during the period. 75.39% of the stock is owned by institutional investors.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.